What is the Purpose of this Study?
Primary Objectives: 1) To evaluate the safety and tolerability of atacicept 2) To evaluate the effect of atacicept on change from baseline in proteinuria
Eligibility
- * Must have the ability to understand and sign a written informed consent form
- * Male or female of ≥18 years of age
- * Total urine protein excretion ≥1.0 g per 24-hour or urine protein to creatinine ratio (UPCR) ≥1.0 mg/mg based on a 24-hour urine sample during the Screening Period
- * Diagnosis of IgAN as demonstrated by renal biopsy conducted within 10 years
Where can I participate?
Beverly
More about this Clinical Trial
What is the full name of this clinical trial?
A Phase 2 Study to Evaluate the Safety and Efficacy of Atacicept in Multiple Autoimmune Glomerular Diseases